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Sorting Out the Mechanisms of 
Antiarrhythmic Drug Action* 
circuit in humans. we have had until recently a myopic view 
of how drugs can affect the eleclrophysiologic milieu respon- 
sible for ventricular tachycardia. The influence of heart rate, 
chronic mvocardial infarction and autonomic tone an elec- 
tropharmacology has only recently been described in hu- 
mans (2.4.7-l 1). In addition. a nonlinear doselconcentration- FRANCIS E. MARCHLINSKI, MD, FACC ,~  ~, 
Philadelphia. Penn.~ylwnio dependent effect on conduction and refractoriness was 
recently described for pracainamide (12). These data higb- 
light the complex interplay of factors by which antiarrbyth- 
Selection of antiarrbythmic drug therapy for suslained mic agents may influence the initiation and maintenance of 
ventricular arrhythmias. The “best” antiarrhytbmic agent is ventricular tachycardia. 
frequently chosen on the basis of its side effect profile or Approach taJhldringthee~tsdantiarrhy(bmicdrugs in 
ease of short or long!..rrr. administration, or both, rather than vetttriculpr tacbycardis. In lieu of our ability to record from 
because of any electrocxdiographic (ECG) change observed all of the reentrant circuit in humans before and after drug 
during sinus rhythm or any measured electrophysiolwzic administration. we are left with two a~woacbes to tin 
effecion cond&ion, refractoriness or excitability (I). An 
agent or agents known to produce significant slowing in 
tachycxdia rate will be selected only when the desired end 
paint oftherapy is a marked slowing in the rate of ventricular 
txhycardia and not arrhythmia prevention. Even then, 
predicting the degree of slowing in the rate of ventricular 
tachycardia in response to a drug has been difficult (Z-4). 
Our lack of understanding of the mechanism of drug 
etTicacy stems in large part from our limited understanding of 
the mechanism of ventricular tachycardia in humans and 
from our relatively primitive recording capabilities. Even 
with ventricular tachycardia in the sating of chronic core- 
nary artery disease, where evidence suggests a reentrant 
mechanism, our inability to record directly from all compo- 
nents of the presumed reentrant circuit in humans has 
precluded a complete understanding of factors responsible 
for initiation and wmetuation of the arrhvthmia. Chronic 
myocardial infar&on.with both resultant marked fiber dis- 
array and anisotropic conduction adds a degree of electro- 
physiologic complexity that is beyond that of the reentrant 
supra~entricular arrhythmias from which we can frequently 
record directly from multiple parts of the reentrant circuit 
IC LI 
insight into the mechanism of drug x&m in ventricular 
tachycardia. The first approach is to determine the response 
of the tachycardia to extrastimuli introduced over a wide 
range of coupling intervals before and after drug administra- 
tion. For example, a flat resetting response after drug 
administration, suggests the presence of an excitable gap and 
indicates that the decrease in tachycardia rate observed after 
drug administration is probably a result of slowing in con- 
duction velocity rather than prolongation of refractoriness 
(13). 
The second possible avenue for srudying the e&c18 of 
ondarrhythmic drugs on sustained ventricular arrhyrhmiar 
is to correlate measured changes in conduction, refractori- 
ness and excitability with the ability to induce the ventricular 
arrhythmia or with the change in cycle length of ventricular 
tachycardia if the arrhythmia remains inducible (4.14). In 
performing such analyses, one should refrain from implying 
a definite casual relation from demonstrated statistically 
significant associations. The association may represent a 
nonspecific drug effect that may lx unrelated to the mecha- 
nism of drug action in preventing ventricular tachywdia 
induction or in slowing its rate. One should also attempt to 
I-‘.“,. 
In addition to our limited ability to record from and thus 
define changes over a maximal range of rates and, when 
characterize lhe presumed reentrant ventricular tachycardia 
possible, define changes for recordings made from both 
normal and abnormal (usually chronically infarcted) myocar- 
dium. An attempt should be made to document the relation 
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The present study. ‘The retrospective analysis by Kus et 
al. (14) reported in this issue of the Journal represents one of 
the first attempts to establish a relatron between the effecis 
of an atttiarrhythmic drug (propafenone) on indexer of 
conduction and refractoriness and the ability to induce 
ventricular tachycardia or the degree of slowing of ventric- 
ular tachycardia that remains inducible. The restdts are 
excitingand provocative. One of the most rurprising findings 
was the inverse relation between the serum propafenone 
concentration and the degree of insrease in right ventricular 
refractoriness and paced QRS duration. The patients with 
the smallest change in these electrophysiology mdcxes ap- 
peared to have their arrhythmias successfully prevented by 
propafenone. P.s mentioned. caution should be used to avold 
implicating a casual relation from the observed assocnuon. 
It is also possible that the patients most likely respond to the 
dtug with noninducibility of ventricular tachycardia had a 
smalkrincrement in conduction intervals during pacing after 
propafenone administration because they had fewer areas of 
slow conduction before drug therapy. It has been demon- 
strated (9) that antiarrhythmic drugs have a greater affect on 
conduction in abnormal infarcted myocardium. In addition. 
the study by Kus and colleagues (14) has not completely 
ruled out the possibility that propafenone slows the rate of 
ventricular tachycardia by slowing conduction velocity. 
Conduction changes at more rapid paced cycle lengtbr were 
not indexed after treatment with ~ropafenone. Wheo ven- 
tricular tachycardia rates differ &k&y. percent change in 
ventricular tachycardii rate may correlate poorly with the 
degree d change in paced QRS duration at a fixed slower 
rate. Utis is particularly true when mzked cycle length- 
decendent effects on conduction zftter dtw administration 
h&e been demonstrated. as is the case forpropafenone. 
The investinators (14) indicated that thev had some diffi- 
cttlty establish& thereproducibility of conboction intervals 
at faster heart rates. This difficulty is exemplified by the 
patient who demonstrated a rate-dependent decrease in the 
&ent change in paced QRS duration after propafenone 
administration from a 50% increase at a oaced cvcle length of 
600 ms to att increase of 440% ate paced cycle-length if4W 
ms. One also most recognize the potential for amplifying 
measorement errors when reporting results as the percent 
change between two measurements. Despite these limita- 
tions, the work by Kus et al. (14) begins to fill the large gap 
of information that needs to be acquired related to the 
assesstttent of the dynamic electrophysiologic effects of 
antiarrhythmic dross and the relation of these changes to 
alterations in arrhythmia inducibility and rate. It is hopeful 
that this rype of information will ultimately lead to the ube of 
sprclfic dntwrh)throic therapy based on predictable electro- 
pharmacology and not solely on the nesd to avoid ,, specrfic 
drug side ekct. 
